Free Trial
NASDAQ:TMDX

TransMedics Group (TMDX) Stock Price, News & Analysis

TransMedics Group logo
$112.46 -12.32 (-9.87%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$112.74 +0.29 (+0.25%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TransMedics Group Stock (NASDAQ:TMDX)

Key Stats

Today's Range
$109.59
$123.50
50-Day Range
$92.21
$143.04
52-Week Range
$55.00
$177.37
Volume
2.55 million shs
Average Volume
1.38 million shs
Market Capitalization
$3.80 billion
P/E Ratio
82.69
Dividend Yield
N/A
Price Target
$127.33
Consensus Rating
Moderate Buy

Company Overview

TransMedics Group Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

TMDX MarketRank™: 

TransMedics Group scored higher than 44% of companies evaluated by MarketBeat, and ranked 558th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    TransMedics Group has only been the subject of 3 research reports in the past 90 days.

  • Read more about TransMedics Group's stock forecast and price target.
  • Earnings Growth

    Earnings for TransMedics Group are expected to grow by 43.00% in the coming year, from $1.00 to $1.43 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TransMedics Group is 82.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.92.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TransMedics Group is 82.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.10.

  • Price to Book Value per Share Ratio

    TransMedics Group has a P/B Ratio of 16.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about TransMedics Group's valuation and earnings.
  • Percentage of Shares Shorted

    25.56% of the float of TransMedics Group has been sold short.
  • Short Interest Ratio / Days to Cover

    TransMedics Group has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in TransMedics Group has recently increased by 2.29%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    TransMedics Group does not currently pay a dividend.

  • Dividend Growth

    TransMedics Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    25.56% of the float of TransMedics Group has been sold short.
  • Short Interest Ratio / Days to Cover

    TransMedics Group has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in TransMedics Group has recently increased by 2.29%, indicating that investor sentiment is decreasing.
  • News Sentiment

    TransMedics Group has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for TransMedics Group this week, compared to 18 articles on an average week.
  • Search Interest

    17 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,512,613.00 in company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of TransMedics Group is held by insiders.

  • Percentage Held by Institutions

    99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about TransMedics Group's insider trading history.
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Stock News Headlines

Top Earnings Movers May 2025 Mid-Caps blurred - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.
Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May
TransMedics Group and two other mid-cap names just posted dominant performances in Q1, smashing forecasts set by Wall Street analysts.
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

TMDX Stock Analysis - Frequently Asked Questions

TransMedics Group's stock was trading at $62.35 at the beginning of the year. Since then, TMDX shares have increased by 80.4% and is now trading at $112.46.

TransMedics Group, Inc. (NASDAQ:TMDX) issued its earnings results on Thursday, May, 8th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. TransMedics Group's revenue for the quarter was up 48.2% compared to the same quarter last year.
Read the conference call transcript
.

TransMedics Group (TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

Top institutional investors of TransMedics Group include Zevenbergen Capital Investments LLC (0.36%), Harbour Capital Advisors LLC (0.02%), Sapient Capital LLC (0.01%) and Silver Oak Securities Incorporated (0.01%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Miriam Provost, Stephen Gordon, Nicholas Corcoran, Tamer I Khayal, John F Carey, Anil P Ranganath, David Weill, Edward M Basile, Stephanie Lovell and Laura Damme.
View institutional ownership trends
.

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/08/2025
Today
7/12/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TMDX
CIK
1756262
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

High Price Target
$178.00
Low Price Target
$75.00
Potential Upside/Downside
+13.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.36
Trailing P/E Ratio
82.69
Forward P/E Ratio
112.46
P/E Growth
N/A
Net Income
$35.46 million
Net Margins
10.03%
Pretax Margin
10.25%
Return on Equity
21.88%
Return on Assets
6.15%

Debt

Debt-to-Equity Ratio
1.92
Current Ratio
9.10
Quick Ratio
8.32

Sales & Book Value

Annual Sales
$441.54 million
Price / Sales
8.61
Cash Flow
$1.48 per share
Price / Cash Flow
75.84
Book Value
$6.81 per share
Price / Book
16.51

Miscellaneous

Outstanding Shares
33,820,000
Free Float
31,456,000
Market Cap
$3.80 billion
Optionable
Optionable
Beta
2.06
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:TMDX) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners